
    
      Ceritinib that has been approved for patients with metastatic non-small cell lung cancer
      (NSCLC) by the US Food and Drug Administration (FDA). While ceritinib is not currently
      FDA-approved specifically in melanoma, researchers believe ceritinib may also help keep
      melanoma cancer cells from growing and therefore potentially help patients with melanoma as
      well. Trametinib is currently FDA-approved for melanoma with a BRAFV600-mutation.
    
  